908 Devices (MASS) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
15 Jan, 2026Executive summary
Q3 2024 revenue reached $16.8 million, up 17% year-over-year, driven by newly acquired handheld products, but below expectations due to delayed government and international orders.
Revenue for the nine months ended September 30, 2024 was $40.8 million, up 14% year-over-year; LTM revenue was $55 million, with a global presence in 55+ countries and 3,200+ units sold.
Net loss widened to $52.8 million for the nine months, driven by a $30.5 million goodwill impairment and higher operating expenses.
Completed acquisition of RedWave Technology, expanding the forensics portfolio and contributing $6.3 million in revenue; integration and operational synergies are ongoing.
Structural changes include manufacturing consolidation, 11% workforce reduction, and sales organization optimization to improve efficiency.
Financial highlights
Q3 2024 revenue was $16.8 million, up 17% year-over-year; nine-month revenue was $40.8 million, up 14% year-over-year.
Handheld revenue was $14 million in Q3, up 19% year-over-year; desktop revenue was $2.8 million, up 8%.
Recurring revenue grew to $6.1 million in Q3 (36% of total), and 39% of YTD revenue, up from 33% in 2023.
Gross margin was 50% GAAP and 55% adjusted in Q3; YTD adjusted gross margin was 56%.
Cash, cash equivalents, and marketable securities totaled $71.7 million at quarter-end, with no debt.
Outlook and guidance
2024 revenue guidance lowered to $56–$58 million, representing 11–15% growth over 2023, including ~$10 million from RedWave.
Management expects continued operating losses as investments in R&D, sales, and manufacturing scale; cash on hand expected to fund operations for at least 12 months.
Adjusted gross margin expected in the mid-50% range for 2024, with further expansion in 2025.
2025 anticipated as a transformational year with margin expansion and cost optimization.
Restructuring and manufacturing consolidation are aimed at reducing annual cash burn and improving efficiency in 2025.
Latest events from 908 Devices
- Transformation and innovation in handheld detection devices drive strong growth and profitability.MASS
Sidoti March Small-Cap Virtual Conference18 Mar 2026 - Strong growth, innovation, and global expansion set the stage for profitability by 2027.MASS
Leerink Global Healthcare Conference 20269 Mar 2026 - Up to $100 million in securities to fund growth in handheld chemical analysis markets.MASS
Registration Filing9 Mar 2026 - Handheld detection tools, new products, and software drive growth and recurring revenue in 2026.MASS
TD Cowen 46th Annual Health Care Conference4 Mar 2026 - 2025 revenue rose 18% to $56.2M, margins hit 57%, and Q4 Adjusted EBITDA turned positive.MASS
Q4 20253 Mar 2026 - Q2 revenue up 16% to $14M; 2024 outlook reaffirmed at $63–$65M, with strong handheld growth.MASS
Q2 20242 Feb 2026 - Handheld growth, RedWave integration, and innovation set the stage for future acceleration.MASS
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026 - RedWave acquisition and product innovation drive growth, margin gains, and market expansion.MASS
The 44th Annual William Blair Growth Stock Conference31 Jan 2026 - Portfolio expansion, RedWave synergies, and operational changes position for growth in 2025.MASS
Stifel 2024 Healthcare Conference13 Jan 2026